Viatris Closes $36.50-a-Share Takeover of Pacira
PCRX sits 94% above its 52-week low of $18.8.
Summary
Viatris has closed its acquisition of Pacira at $36.50 per share in cash, the same terms announced on October 8. That price pins Pacira near its 52-week high, so the stock now trades on deal mechanics rather than fundamentals. Viatris expects the acquisition to contribute total revenue of $90 million to $100 million for the remainder of 2026. The close follows Pacira's board recommendation of the tender offer on October 30 and its decision to skip Q3 reporting and withdraw 2026 guidance on November 5. Two New York state suits and fifteen demand letters alleging the 14D-9 omitted material information, disclosed November 12, did not stop the deal from completing. Viatris is the acquirer here; Pacira shareholders receive the fixed cash consideration.
At the time of this announcement, PCRX was trading at $36.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.